Toggle light / dark theme

The Colombian protests began on April 28, 2021, sparked by a tax reform opposed by the working class and middle-class Colombians.

Amnesty International’s use of AI generated images to commemorate the second anniversary of Colombian protests has sparked a debate over the credibility of advocacy groups and media organizations in their coverage of war-inflicted zones.

Amnesty’s Norway regional account posted three images in a series of tweets. The first depicted a crowd of armor-clad police officers; the second featured a police officer with a red splotch on his face, and the third of a protester being dragged away by police officials.


Amnesty International/Twitter.

Indigo naturalis is a blue dye in ancient, as well as an extensive used traditional Chinese medicine. It has a wide spectrum of pharmacological properties and can be used to treat numerous ailments such as leukemia, psoriasis, and ulcerative colitis. This article aims to expand our understanding of indigo naturalis in terms of its chemical constituents, pharmacological action and clinical applications.

We searched PubMed, web of science, CNKI, Google academic, Elsevier and other databases with the key words of “Indigo naturalis”, and reviewed and sorted out the modern research of indigo naturalis based on our research results.

We outlined the traditional manufacturing process, chemical composition and quality control of indigo naturalis, systematically reviewed traditional applictions, pharmacological activities and mechanism of indigo naturalis, and summarized its clinical trials about treatment of psoriasis, leukemia and ulcerative colitis.

Year 2015 😗😁


Indigo-Clean is a new light that is capable of killing bacteria. Used in a healthcare settings, the device could help prevent the spread of dangerous microorganisms, including Methicillin-resistant Staphylococcus aureus (MRSA), a bacterium responsible for several difficult-to-treat infections in humans.

Bacteria in the air absorb the indigo-colored light, which then creates a chemical reaction within the microorganism. This creates an environment that acts like bleach, killing the microscopic lifeform, reports Tech Times.

The new bacteria-killing light was introduced to the public at an annual meeting of the Association for Professionals in Infection Control and Epidemiology. The device was first constructed in 2008 and has undergone real-world testing at the University of Strathclyde in Glasgow. Health professionals have noted the effectiveness of the light at killing bacteria that could otherwise spread to patients.

A study has found that a mitochondrial disease in newborns shows cancer-like changes in proliferating cells, causing tissues to age prematurely. The finding is a significant step forward in understanding the syndrome and developing treatments for mitochondrial diseases.

GRACILE syndrome, a that is one of the Finnish heritage diseases, shows altered and proliferation resembling that of . In the future, similar could potentially be treated by limiting excessive cell proliferation. This is demonstrated in a study led by docent Jukka Kallijärvi and professor emerita Vineta Fellman that was carried out at the Folkhälsan Research Center and the University of Helsinki and published in Nature Communications in April 2023.

Mitochondria are organelles responsible for a large portion of cellular energy metabolism. Mutations in genes required for mitochondrial functions cause mitochondrial diseases in humans. GRACILE syndrome is caused by a malfunction in the respiratory chain, the very system the mitochondria utilize to generate cellular energy. The onset of the syndrome is in the fetal period, manifesting after birth as a liver and kidney disease with severe metabolic complications. Newborns with the syndrome usually only survive a few weeks.

A major impediment to treating the deadly brain cancer glioblastoma has been that the most potent chemotherapy can’t permeate the blood-brain barrier to reach the aggressive brain tumor.

But now Northwestern Medicine scientists report results of the first in-human clinical trial in which they used a novel, skull-implantable ultrasound device to open the and repeatedly permeate large, critical regions of the to deliver chemotherapy that was injected intravenously.

The four-minute procedure to open the blood-brain barrier is performed with the patient awake, and patients go home after a few hours. The results show the treatment is safe and well tolerated, with some patients getting up to six cycles of treatment.

Long-term sufferers of chronic back pain experienced dramatic reductions in pain and related disability that remained at their one-year follow-up after taking part in a new treatment tested by Curtin-Macquarie-Monash University research.

Published today in the journal The Lancet, the research found large clinically significant improvements in the intensity of pain and pain-related disability among almost 500 people who had been seeking help for their pain for an average of four years before trialing the new treatment.

The treatment, which delivered a health care and work productivity saving of more than $5,000 per person, took a whole-person approach by also helping people to make lifestyle changes aimed at improving their social and emotional health.